Your session is about to expire
← Back to Search
EGCG for Pulmonary Fibrosis
Phase 1
Recruiting
Led By Fernando Martinez, MD
Research Sponsored by Hal Chapman
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Must not have
Estimated glomerular filtration rate (eGFR) of less than 30 mL/min/1.73 m2 within the prior 30 days
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline to 12 weeks
Awards & highlights
Summary
"This trial aims to see if a specific type of imaging test using a collagen-targeted PET probe can help understand the effects of a drug called EGCG and determine the right dosage to use."
Who is the study for?
This trial is for individuals with Pulmonary Fibrosis or Idiopathic Pulmonary Fibrosis. Specific eligibility criteria are not provided, but typically participants would need to meet certain health standards and may be required to have a confirmed diagnosis of the conditions mentioned.
What is being tested?
The study is testing the effects of EGCG at two different doses (300 mg and 600 mg) compared to placebos. It uses a PET imaging probe called Gallium-68 (68Ga)-CBP8 to see if it can show how well EGCG works in treating fibrosis and help choose the right dose.
What are the potential side effects?
While specific side effects are not listed, EGCG is generally considered safe with possible mild side effects like stomach upset or constipation. The PET imaging agent used may cause allergic reactions or discomfort at the injection site.
Eligibility Criteria
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
My kidney function test shows an eGFR below 30.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ from baseline to 12 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline to 12 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in collagen probe uptake over the entire lungs
Other study objectives
Change in peak enhancement over the entire lungs
Change in the area under the curve at 60 seconds over the entire lungs
Change in the full width at half maximum over the entire lungs
+2 moreTrial Design
4Treatment groups
Active Control
Placebo Group
Group I: EGCG 300 mgActive Control2 Interventions
Patients enrolled in this group will be given oral capsule EGCG 300 mg daily with doctor provided anti-fibrotic for 12 weeks.
Group II: EGCG 600 mgActive Control2 Interventions
Patients enrolled in this group will be given oral capsule EGCG 600 mg daily with doctor provided anti-fibrotic for 12 weeks.
Group III: Placebo for EGCG 300 mgPlacebo Group2 Interventions
Patients enrolled in this group will be given oral capsule Placebo daily for 12 weeks with doctor provided anti-fibrotic. The number of placebo capsules will be equal to that of 300 mg EGCG.
Group IV: Placebo for EGCG 600 mgPlacebo Group2 Interventions
Patients enrolled in this group will be given oral capsule Placebo daily for 12 weeks with doctor provided anti-fibrotic. The number of placebo capsules will be equal to that of 600 mg EGCG.
Find a Location
Who is running the clinical trial?
Cornell UniversityOTHER
170 Previous Clinical Trials
14,091,096 Total Patients Enrolled
1 Trials studying Idiopathic Pulmonary Fibrosis
50 Patients Enrolled for Idiopathic Pulmonary Fibrosis
National Heart, Lung, and Blood Institute (NHLBI)NIH
3,889 Previous Clinical Trials
47,834,185 Total Patients Enrolled
22 Trials studying Idiopathic Pulmonary Fibrosis
4,579 Patients Enrolled for Idiopathic Pulmonary Fibrosis
Massachusetts General HospitalOTHER
2,993 Previous Clinical Trials
13,230,699 Total Patients Enrolled
2 Trials studying Idiopathic Pulmonary Fibrosis
150 Patients Enrolled for Idiopathic Pulmonary Fibrosis
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger